8-K: Entera Bio Secures $275M for Osteoporosis Drug; FDA Alignment

Entera Bio Ltd. announced a $275 million private placement and positive FDA feedback for its oral osteoporosis drug EB613, positioning it for Phase 3 trials and NDA submission.

Summary

• Entera Bio Ltd. reported its Q2 2026 financial results and provided significant business updates.
• The company received FDA alignment on a 12-month Phase 3 registrational study for EB613, an oral anabolic tablet for postmenopausal women with osteoporosis, to support an NDA submission.
• A $275 million oversubscribed private placement, led by BVF Partners L.P., was completed to fund the EB613 Phase 3 program through anticipated NDA submission.
• The Phase 3 study for EB613 is planned to initiate in late 2026, with topline data expected in the second half of 2028.
• Preclinical data for EB612, an oral peptide replacement tablet for hypoparathyroidism, showed promising results, with an IND filing planned for the first half of 2027.
• Preclinical data for EB618, an oral dual GLP-1/glucagon tablet for obesity, also demonstrated robust bioavailability and tolerability.
• As of June 30, 2026, the company had $11.3 million in cash and cash equivalents, with pro forma cash expected to exceed $275 million post-placement, sufficient to fund operations into 2030.
• Net loss for the three months ended June 30, 2026, was $7.3 million, or $0.14 per share, compared to $2.7 million, or $0.06 per share, in the prior year period.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, driven by significant funding, FDA alignment on a key trial, and strong preclinical data for multiple pipeline assets.

Positives

• Secured $275 million in an oversubscribed private placement, significantly bolstering financial resources.
• Received FDA alignment on a 12-month Phase 3 registrational study for EB613, a critical step towards NDA submission.
• Positive preclinical data for EB612 (hypoparathyroidism) and EB618 (obesity) indicate strong pipeline development.
• The capital raise is expected to fund EB613 through NDA submission and extend cash runway into 2030.
• Phase 1 data for single-tablet EB613 showed PK/PD profiles comparable to multi-tablet EB613 and Forteo.
• Key Opinion Leaders (KOLs) highlighted the unmet need for oral anabolic therapy and EB613's potential.
• EB613 Phase 2 data demonstrated positive effects on bone mineral density and bone turnover biomarkers.
• The company has a clear plan for Phase 3 initiation of EB613 in late 2026.

Negatives

• Net loss increased to $7.3 million for the three months ended June 30, 2026, from $2.7 million in the prior year period.
• Research and development expenses more than doubled to $3.2 million from $1.5 million year-over-year, reflecting increased program costs.
• The company is still in the development stage with no approved products on the market.

Risks

• The success of the EB613 Phase 3 registrational study is subject to achieving primary endpoints and FDA acceptance.
• There is no assurance that the FDA will accept the proposed NDA package, including the scientific bridge analysis with Forteo and the bone biopsy sub-study.
• The timing and results of clinical trials, including the planned Phase 3 study for EB613 and IND filings for EB612 and EB618, may be subject to unexpected changes.
• Entera relies on third parties to conduct its clinical trials, introducing potential risks related to performance and oversight.
• The company's ability to obtain and maintain regulatory approvals for its product candidates is not guaranteed.
• Entera's ability to continue as a going concern is dependent on securing future financing and achieving profitability.
• Competition from existing treatments and other drugs in development for osteoporosis, hypoparathyroidism, and obesity poses a significant risk.

Future Outlook

The company anticipates initiating the registrational Phase 3 study for EB613 in late 2026, with topline results expected in the second half of 2028. An IND application for EB612 is planned for the first half of 2027. The substantial private placement is expected to provide sufficient funding to support the EB613 Phase 3 program through anticipated NDA submission and extend the company's cash runway into 2030.

Management Comments

• "The first half of 2026 marked one of the most consequential periods in Entera's history. Since 2022, our core team embarked upon a journey of deconstruction and reconstruction to advance our science and optimize our pipeline."
• "Despite scarce resources and particularly turbulent times, today, our N-Tab platform is developing one of the richest pipelines of clinical and near-clinical first in class oral peptide assets; and we have garnered the trust of global talent, luminaries, and financiers who support our mission and vision."
• "Osteoporosis is one of the foremost underserved health issues globally, and associated fracture rates continue to rise despite existing treatments. Our discussions with patients and their caregivers across primary care, gynecology, orthopedic surgery, rheumatology and endocrinology acknowledge the urgent need for new treatments, especially, an oral anabolic therapy. We are developing EB613 to address this treatment gap. Our plan is to do the same with EB612 for patients with hypoparathyroidism, also a women-centric condition."
• "The capital raising transaction we announced on July 27, 2026, led by BVF is transformational for Entera. To our knowledge, the transaction is the largest biotech PIPE and the 9th largest PIPE, inclusive of the high-tech sector, on record in Israel. So, we shattered a few records and moving forward, we intend to continue to shatter more records across all our programs with a cohesive, global team of colleagues who are obsessed with our vision and steadfast in our execution."

Industry Context

StockSavvy.ai notes that Entera Bio's focus on oral peptide therapies addresses a significant trend in the pharmaceutical industry towards developing more convenient and patient-friendly drug delivery methods. The company's progress in osteoporosis, hypoparathyroidism, and obesity aligns with major therapeutic areas experiencing high unmet needs and significant market potential.

Comparison to Industry Standards

• The $275 million private placement is highlighted as the largest biotech PIPE and 9th largest PIPE overall in Israel on record, indicating strong investor confidence and market reception.
• The Phase 3 study design for EB613, utilizing a 505(b)(2) pathway and incorporating a scientific bridge analysis with Eli Lilly's Forteo, is a common strategy for leveraging existing drug data to expedite development.
• The company's N-Tab platform aims to deliver peptides orally, a significant advancement over traditional injectable therapies, which is a key differentiator in the peptide therapeutics market.

Corporate Governance

Stakeholder Impact

• Shareholders: The significant capital raise and positive clinical development updates are expected to enhance shareholder value, though increased R&D spending has led to a higher net loss in the short term.
• Creditors: The substantial cash infusion provides greater assurance of the company's ability to meet its financial obligations.
• Employees: Continued development of the pipeline and potential future commercialization offers job security and growth opportunities.
• Collaborators (e.g., OPKO Health): Progress in the EB612 program strengthens the collaborative relationship and potential for future revenue streams.

Next Steps

• Initiate the registrational Phase 3 study for EB613 in late 2026.
• Submit an Investigational New Drug (IND) application for EB612 in the first half of 2027.
• Submit data from the EB613 Phase 3 study, including up to 18 months of safety data, as part of the 120-day safety update to the NDA.
• Complete the 2-year open-label extension study for EB613 to further characterize treatment durability and safety.
• Evaluate the initiation of EB618 clinical development based on Phase 1 studies of subcutaneous injectable OXM being conducted by OPKO.

Key Dates

Recommendation

The substantial capital raise, FDA alignment on a pivotal Phase 3 trial for a key asset (EB613), and promising preclinical data for other pipeline candidates (EB612, EB618) represent significant de-risking events and catalysts for future growth. The extended cash runway into 2030 provides ample time for clinical development and regulatory milestones.

Keywords

Osteoporosis, EB613, Oral Peptide, Phase 3 Trial, FDA, NDA Submission, Hypoparathyroidism, EB612